Cella, David
McKendrick, Jan
Kudlac, Amber
Palumbo, Antonio
Oukessou, Abderrahim
Vij, Ravi
Zyczynski, Teresa
Davis, Catherine
Funding for this research was provided by:
Bristol-Myers Squibb
AbbVie Biotherapeutics
Article History
Received: 26 February 2018
Accepted: 1 August 2018
First Online: 4 September 2018
Compliance with ethical standards
: Institutional review board or independent ethics committee approval and written informed consent from all patients for being included in the study were obtained. The study was performed in accordance with the ethical principles of the Declaration of Helsinki and in compliance with national laws.
: David Cella has served as a consultant for and/or received research funding from AbbVie, Alexion, Astellas, Bayer, Biogen Idec, Bristol-Myers Squibb, Celgene, Clovis Oncology, Daiichi Sankyo, Eli Lilly, Evidera, Exelixis, FibroGen, Genentech, GlaxoSmithKline, Helsinn Therapeutics, Immunogen, Ipsen Pharma, Janssen, Lexicon Pharmaceuticals, Merck, Novartis, Onconova, and Pfizer. Jan McKendrick and Amber Kudlac are employees of PRMA Consulting Ltd. Antonio Palumbo has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Genmab, Janssen-Cilag, Millennium, Novartis, Onyx, and Sanofi, and served in a consulting or advisory role for Amgen, Bristol-Myers Squibb, Celgene, Genmab, Janssen-Cilag, Millennium, and Onyx. Abderrahim Oukessou, Teresa Zyczynski, and Catherine Davis are employees of Bristol-Myers Squibb. Ravi Vij has received honoraria from Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, Onyx, and Takeda; served in a consulting or advisory role for Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, Onyx, and Takeda; received research funding from Onyx and Takeda; and received travel, accommodations, and/or expenses from Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, Onyx, and Takeda.